New Delhi Jan 15: A US based domestic drug company Gilead which sells hepatitis C durg sofosbuvir has been denied its patent by the Indian patent office which proves to be a boost to domestic drug firm Natco Pharma. Gilead sells the drug under the brand name Sovaldi in the US and an order by Deputy Controller of Patents & Designs Hardev Karar said that Gilead failed to prove that were enhancement of therapeutic efficacy in the new discovery. Sovaldi is priced at 84000 USD for a 12 week course in the US which has received criticism from advocates of
